Archemix Corp.

Ophthotech Gets $30M Series B for Trials of Lucentis Add-Ons.
BIOWORLD Today; 12/15/2009; 1346 words; Staff Writer Ophthotech Corp. is expected to announce on Tuesday...BioPharma Inc. (now Facet Biotech Corp.) and Biogen Idec Inc. The two are...complement factor inhibitor licensed from Archemix Corp. That drug is in a Phase I Lucentis...

Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities.
PR Newswire; 12/2/2009; 2340 words; ...Technologies 15 6. CORPORATE DEVELOPMENTS 15 Affymetrix Acquires USB Corp 15 Roche Acquires Ventana Medical Systems 15 Bruker BioSciences...16 Implant Sciences to Acquire Ion Metrics 17 NascaCell and Archemix Expand Partnership for Aptamer-Based Drugs 17 DiscoveRx and...

$37M Addition Brings Archemix Series A Financing To $51.75M.
BIOWORLD Today; 11/4/2009; 736 words; Staff Writer Archemix Corp. completed a Series A round that began...will be used, said Martin Stanton, Archemix president and a company founder...November 2001, Cambridge, Mass.-based Archemix licensed the aptamer technology from...

Appointments And Advancements.
BIOWORLD Today; 11/4/2009; 1087 words; ...Susan Wyant. Advanced Viral Research Corp., of Yonkers, N.Y., added...president and chief information officer. Archemix Corp., of Cambridge, Mass., appointed...chief operating officer. Connetics Corp., of Palo Alto, Calif., appointed...

Other News To Note.
BIOWORLD Today; 11/3/2009; 2473 words; ...expects to report results in late 2005 or early 2006. o Archemix Corp., of Cambridge, Mass., received an undisclosed milestone...11 cents to close at 56 cents. o Generex Biotechnology Corp., of Toronto, said its subsidiary, Antigen Express...